PT - JOURNAL ARTICLE AU - Johnson, Emily J. AU - González-Peréz, Vanessa AU - Tian, Dan-Dan AU - Lin, Yvonne S. AU - Unadkat, Jashvant D. AU - Rettie, Allan E. AU - Shen, Danny D. AU - McCune, Jeannine S. AU - Paine, Mary F. TI - Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product–Drug Interactions: A NaPDI Center Recommended Approach AID - 10.1124/dmd.118.081273 DP - 2018 Jul 01 TA - Drug Metabolism and Disposition PG - 1046--1052 VI - 46 IP - 7 4099 - http://dmd.aspetjournals.org/content/46/7/1046.short 4100 - http://dmd.aspetjournals.org/content/46/7/1046.full SO - Drug Metab Dispos2018 Jul 01; 46 AB - Pharmacokinetic interactions between natural products (NPs) and conventional medications (prescription and nonprescription) are a longstanding but understudied problem in contemporary pharmacotherapy. Consequently, there are no established methods for selecting and prioritizing commercially available NPs to evaluate as precipitants of NP–drug interactions (NPDIs). As such, NPDI discovery remains largely a retrospective, bedside-to-bench process. This Recommended Approach, developed by the Center of Excellence for Natural Product Drug Interaction Research (NaPDI Center), describes a systematic method for selecting NPs to evaluate as precipitants of potential clinically significant pharmacokinetic NPDIs. Guided information-gathering tools were used to score, rank, and triage NPs from an initial list of 47 candidates. Triaging was based on the presence and/or absence of an NPDI identified in a clinical study (≥20% or <20% change in the object drug area under the concentration vs. time curve, respectively), as well as mechanistic and descriptive in vitro and clinical data. A qualitative decision-making tool, termed the fulcrum model, was developed and applied to 11 high-priority NPs for rigorous study of NPDI risk. Application of this approach produced a final list of five high-priority NPs, four of which are currently under investigation by the NaPDI Center.